N1-methyladenosine (m1A) is a prevalent RNA modification widely affecting RNA structural stability, folding, and interactions with proteins. Recently, there have been increasing reports on the roles of m1A regulators in tumors. However, their mechanisms and clinical relevance remain unclear. This study systematically evaluates the epigenetic characteristics and clinical relevance of m1A regulators using bioinformatic methods. Our results show widespread gene expression changes for m1A regulators, which are related to the activation and inhibition of carcinogenic pathways and overall patient survival. Collectively, this investigation provides new insights into assessing tumor prognosis and targeted therapy.
Get full access to this article
View all access options for this article.
References
1.
AliA.T., IdaghdourY., and HodgkinsonA. (2020). Analysis of mitochondrial m1A/G RNA modification reveals links to nuclear genetic variants and associated disease processes. Commun Biol 3,147.
2.
BaiY., YangC., WuR., HuangL., SongS., LiW., et al. (2019). YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma. Front Oncol 9,332.
3.
BrownJ., StepienA.J., and WillemP. (2020). Landscape of copy number aberrations in esophageal squamous cell carcinoma from a high endemic region of South Africa. BMC Cancer 20,281.
4.
ChenH., ChenC., YuanX., XuW., YangM.Q., LiQ., et al. (2020). Identification of immune cell landscape and construction of a novel diagnostic nomogram for Crohn's disease. Front Genet 11,423.
5.
ChenL., WangP., BahalR., ManautouJ.E., and ZhongX.B. (2019a). Ontogenic mRNA expression of RNA modification writers, erasers, and readers in mouse liver. PLoS One 14,e0227102.
6.
ChenM., WeiL., LawC.T., TsangF.H., ShenJ., ChengC.L., et al. (2018). RNA n6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology, 67, 2254–2270.
7.
ChenZ., QiM., ShenB., LuoG., WuY., LiJ., et al. (2019b). Transfer RNA demethylase ALKBH3 promotes cancer progression via induction of tRNA-derived small RNAs. Nucleic Acids Res, 47, 2533–2545.
8.
ChengM., ShengL., GaoQ., XiongQ., ZhangH., WuM., et al. (2019). The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network. Oncogene, 38, 3667–3680.
9.
DaiX., WangT., GonzalezG., and WangY. (2018). Identification of YTH domain-containing proteins as the readers for n1-methyladenosine in RNA. Anal Chem, 90, 6380–6384.
10.
DeepaA., NaveenaK., and AnindyaR. (2018). DNA repair activity of Fe(II)/2OG-dependent dioxygenases affected by low iron level in Saccharomyces cerevisiae. FEMS Yeast Res, 18. DOI: 10.1093/femsyr/foy014.
11.
DelaunayS., and FryeM. (2019). RNA modifications regulating cell fate in cancer. Nat Cell Biol, 21, 552–559.
12.
DinescuS., IgnatS., LazarA.D., ConstantinC., NeaguM., and CostacheM. (2019). Epitranscriptomic signatures in lncRNAs and their possible roles in cancer. Genes (Basel) 10,52.
13.
DominissiniD., NachtergaeleS., Moshitch-MoshkovitzS., PeerE., KolN., Ben-HaimM., et al. (2016). The dynamic n(1)-methyladenosine methylome in eukaryotic messenger RNA. Nature, 530, 441–446.
14.
DunnD.B. (1961). The occurrence of 1-methyladenine in ribonucleic acid. Biochim Biophys Acta, 46, 198–200.
15.
EngelM., and ChenA. (2018). The emerging role of mRNA methylation in normal and pathological behavior. Genes Brain Behav 17,e12428.
16.
Esteve-PuigR., ClimentF., PiñeyroD., Domingo-DomenechE., DavalosV., EncuentraM., et al. (2020). Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen conferring poor clinical outcome. Blood [Epub ahead of print]; DOI: 10.1182/blood.2020005823.
17.
FranceschiniA., SzklarczykD., FrankildS., KuhnM., SimonovicM., RothA., et al. (2013). String v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res, 41, D808–D815.
HanD., LiuJ., ChenC., DongL., LiuY., ChangR., et al. (2019). Author correction: anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature 568,E3.
20.
HartT., KomoriH.K., LaMereS., PodshivalovaK., and SalomonD.R. (2013). Finding the active genes in deep RNA-seq gene expression studies. BMC Genomics 14,778.
21.
HuJ., LiR., MiaoH., and WenZ. (2020). Identification of key genes for esophageal squamous cell carcinoma via integrated bioinformatics analysis and experimental confirmation. J Thorac Dis, 12, 3188–3199.
22.
LanQ., LiuP.Y., HaaseJ., BellJ.L., HüttelmaierS., and LiuT. (2019). The critical role of RNA m(6)A methylation in cancer. Cancer Res, 79, 1285–1292.
23.
LiX., XiongX., ZhangM., WangK., ChenY., ZhouJ., et al. (2017). Base-resolution mapping reveals distinct m(1)A methylome in nuclear- and mitochondrial-encoded transcripts. Mol Cell, 68, 993–1005.e9.
24.
LiY., XiaoJ., BaiJ., TianY., QuY., ChenX., et al. (2019). Molecular characterization and clinical relevance of m(6)A regulators across 33 cancer types. Mol Cancer 18,137.
25.
LiZ., PengY., LiJ., ChenZ., ChenF., TuJ., et al. (2020). N(6)-methyladenosine regulates glycolysis of cancer cells through PDK4. Nat Commun 11,2578.
26.
LiangS., GuanH., LinX., LiN., GengF., and LiJ. (2020). METTL3 serves an oncogenic role in human ovarian cancer cells partially via the Akt signaling pathway. Oncol Lett, 19, 3197–3204.
27.
LinX., ChaiG., WuY., LiJ., ChenF., LiuJ., et al. (2019). RNA m(6)A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of snail. Nat Commun 10,2065.
28.
LiuJ., GaoM., XuS., ChenY., WuK., LiuH., et al. (2020a). YTHDF2/3 are required for somatic reprogramming through different RNA deadenylation pathways. Cell Rep 32,108120.
29.
LiuS., LiQ., ChenK., ZhangQ., LiG., ZhuoL., et al. (2020b). The emerging molecular mechanism of m(6)A modulators in tumorigenesis and cancer progression. Biomed Pharmacother 127,110098.
30.
NiuY., WanA., LinZ., LuX., and WanG. (2018). N(6)-methyladenosine modification: a novel pharmacological target for anti-cancer drug development. Acta Pharm Sin B, 8, 833–843.
31.
OerumS., DégutC., BarraudP., and TisnéC. (2017). M1a post-transcriptional modification in tRNAs. Biomolecules 7,20.
32.
PiJ., WangW., JiM., WangX., WeiX., JinJ., et al. (2020). YTHDF1 promotes gastric carcinogenesis by controlling translation of FZD7. Cancer Res [Epub ahead of print]; DOI: 10.1158/0008-5472.CAN-20-0066.
33.
SafraM., Sas-ChenA., NirR., WinklerR., NachshonA., Bar-YaacovD., et al. (2017). The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature, 551, 251–255.
34.
Sánchez-VásquezE., Alata JimenezN., VázquezN.A., and Strobl-MazzullaP.H. (2018). Emerging role of dynamic RNA modifications during animal development. Mech Dev, 154, 24–32.
35.
SharmaS., HartmannJ.D., WatzingerP., KlepperA., PeiferC., KotterP., et al. (2018). A single n(1)-methyladenosine on the large ribosomal subunit rRNA impacts locally its structure and the translation of key metabolic enzymes. Sci Rep 8,11904.
36.
ShiQ., XueC., YuanX., HeY., and YuZ. (2020). Gene signatures and prognostic values of m1A-related regulatory genes in hepatocellular carcinoma. Sci Rep 10,15083.
37.
ShimaH., and IgarashiK. (2020). N1-methyladenosine (m1A) RNA modification: the key to ribosome control. J Biochem, 167, 535–539.
38.
SunS., HanQ., LiangM., ZhangQ., ZhangJ., and CaoJ. (2020). Downregulation of m(6)A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non-small cell lung cancer. Thorac Cancer, 11, 3269–3279.
39.
UedaY., OoshioI., FusamaeY., KitaeK., KawaguchiM., JingushiK., et al. (2017). ALKB homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells. Sci Rep 7,42271.
40.
VuL.P., PickeringB.F., ChengY., ZaccaraS., NguyenD., MinuesaG., et al. (2017). The n(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med, 23, 1369–1376.
41.
WangD., HuX., XiaoL., LongG., YaoL., WangZ., et al. (2020a). Prognostic nutritional index and systemic immune-inflammation index predict the prognosis of patients with HCC. J Gastrointest Surg [Epub ahead of print]; DOI: 10.1007/s11605-019-04492-7.
42.
WangQ., ZhangQ., HuangY., and ZhangJ. (2020b). M(1)a regulator trmt10c predicts poorer survival and contributes to malignant behavior in gynecological cancers. DNA Cell Biol, 39, 1767–1778.
43.
WangY., RenF., SongZ., WangX., and MaX. (2020c). Multiomics profile and prognostic gene signature of m6A regulators in uterine corpus endometrial carcinoma. J Cancer, 11, 6390–6401.
44.
XiaoM.Z., LiuJ.M., XianC.L., ChenK.Y., LiuZ.Q., and ChengY.Y. (2020). Therapeutic potential of ALKB homologs for cardiovascular disease. Biomed Pharmacother 131,110645.
45.
YamatoI., ShoM., ShimadaK., HottaK., UedaY., YasudaS., et al. (2012). Pca-1/ALKBH3 contributes to pancreatic cancer by supporting apoptotic resistance and angiogenesis. Cancer Res, 72, 4829–4839.
46.
YangZ., WangT., WuD., MinZ., TanJ., and YuB. (2020). RNA n6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer. J Exp Clin Cancer Res 39,203.
47.
YouC., DaiX., and WangY. (2017). Position-dependent effects of regioisomeric methylated adenine and guanine ribonucleosides on translation. Nucleic Acids Res, 45, 9059–9067.
48.
YueB., SongC., YangL., CuiR., ChengX., ZhangZ., et al. (2019). METTL3-mediated n6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer 18,142.
49.
ZhangC., and JiaG. (2018). Reversible RNA modification n(1)-methyladenosine (m(1)A) in mRNA and tRNA. Genomics Proteomics Bioinformatics, 16, 155–161.
50.
ZhaoX., ChenY., MaoQ., JiangX., JiangW., ChenJ., et al. (2018). Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Biomark, 21, 859–868.
51.
ZhaoY., ShiY., ShenH., and XieW. (2020a). M(6)a-binding proteins: the emerging crucial performers in epigenetics. J Hematol Oncol 13,35.
52.
ZhaoY., ZhaoQ., KaboliP., ShenJ., LiM., WuX., et al. (2019). M1a regulated genes modulate PI3K/AKT/mTOR and ERBB pathways in gastrointestinal cancer. Trans Oncol, 12, 1323–1333.
53.
ZhaoZ., MengJ., SuR., ZhangJ., ChenJ., MaX., et al. (2020b). Epitranscriptomics in liver disease: basic concepts and therapeutic potential. J Hepatol, 73, 664–679.
54.
ZhengQ., GanH., YangF., YaoY., HaoF., HongL., et al. (2020). Cytoplasmic m(1)A reader YTHDF3 inhibits trophoblast invasion by downregulation of m(1)A-methylated IGF1R. Cell Discov 6,12.
55.
ZhouJ., WangJ., HongB., MaK., XieH., LiL., et al. (2019). Gene signatures and prognostic values of m6a regulators in clear cell renal cell carcinoma—a retrospective study using TCGA database. Aging (Albany NY), 11, 1633–1647.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
